Significant advances over the past few decades have dramatically improved HIV treatment and for many of the 1.1 million people living with HIV in the U.S.,1 HIV is considered a manageable condition.
For years, the HIV standard of care has been three-drug regimens, typically a single tablet that includes three antiretroviral (ARV) drugs to suppress the HIV virus. Now, the FDA has expanded the indication of an HIV treatment comprising two drugs, making it available not only for adults who have never been on HIV treatment but also those who are virologically suppressed and wish to switch treatments. This two-drug regimen reduces the number of ARVs people living with HIV are exposed to each day, eliminating the need for an additional medication in a person’s regimen.
On September 17, Dr. Kimberly Smith, Head of Research & Development at ViiV Healthcare, will be available to discuss the latest in HIV treatment research including new data, challenges that many people living with HIV face, and how two-drug regimens are changing the ARV treatment landscape.
